You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Atopic Dermatitis Journal Club: What's New Now

  • Authors: Lawrence Eichenfield, MD; Emma Guttman-Yassky, MD, PhD; Linda Stein Gold, MD; Jacob P. Thyssen, MD, PhD
  • CME Released: 11/23/2019
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 11/23/2020
Start Activity


Target Audience and Goal Statement

This activity is intended for dermatologists, allergists, clinical immunologists, and primary care physicians.

The goal of this activity is to review the latest data in atopic dermatitis (AD) published and presented at major dermatology and allergy meetings as well as discuss how the latest clinical data on therapies for AD can be integrated into clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest data in AD presented at major dermatology and allergy meetings 
  • Have greater competence related to
    • Integrating the latest clinical data on therapies for AD into clinical practice in an age-appropriate manner


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • Lawrence Eichenfield, MD

    Professor of Dermatology and Pediatrics
    Vice Chair, Department of Dermatology
    Chief, Pediatric and Adolescent Dermatology
    University of California, San Diego School of Medicine, United States

    Disclosures

    Disclosure: Lawrence Eichenfield, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Almirall Hermal GmbH; Anacor; Cutanea; Dermavant; Dermira; DS Biopharma; Forte; Galderma Laboratories, L.P.; Incyte Corporation; LEO Pharma; Lilly; L'Oreal; Matrisys; Medimetriks; Morphosys; Novan; Novartis Pharmaceuticals Corporation; Ortho Dermatologics; Otsuka Pharmaceutical Co., Ltd.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme Corporation;
    Served as a speaker or a member of a speakers bureau for: Ortho Dermatologics;
    Other: Investigator: AbbVie Inc.; LEO Pharma; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme Corporation; DSM: Asana Biosciences; Glenmark

Panelists

  • Emma Guttman-Yassky, MD, PhD

    Sol and Clara Kest Professor
    Vice Chair for Research at the Department of Dermatology
    Director of the Center for Excellence in Eczema
    Director of the Laboratory of Inflammatory Skin Diseases at the Icahn School of Medicine at Mount Sinai Medical Center
    New York, New York, United States

    Disclosures

    Disclosure: Emma Guttman-Yassky, MD, PhD , has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Almirall Hermal GmbH ; Amgen Inc.; Asana Biosciences; Cara Therapeutics; Celgene Corporation; Concert Pharmaceuticals; DBV Therapeutics; Dermira Inc.; DS Biopharma; EMD Serono; Escalier Biosciences; Galderma Laboratories, L.P.; Glenmark; Kyowa Kirin, LEO Pharma, Lilly, Mitsubishi;Tanabe, Novartis, Pfizer, RAPT Therapeutics, Regeneron Pharmaceuticals Inc.; Sanofi; Sienna Biopharmaceuticals; Union Therapeutics
    Received grants for clinical research from: AbbVie Inc.; Almirall Hermal GmbH ; AnaptysBio; Asana Biosciences; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Dermavant; DS Biopharma; Galderma Laboratories, L.P.; Glenmark; Innovaderm; Janssen Biotech; Kiniska Pharma; LEO Pharma; Lilly; Medimmune; Sienna Biopharma; Novan; Novartis; Ralexar; Regeneron Pharmaceuticals Inc.; Pfizer; UCB; Union Therapeutics

  • Linda Stein Gold, MD

    Director of Dermatology Clinical Research
    Henry Ford Health System
    Detroit, Michigan, United States

    Disclosures

    Disclosure: Linda Stein Gold, MD , has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Dermira Inc.; Foamix; Galderma Laboratories, L.P.; LEO Pharma; Ortho Dermatologics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; SolGel
    Served as a speaker or a member of a speakers bureau for: Dermira Inc.; Foamix; Galderma Laboratories, L.P.; LEO Pharma; Ortho Dermatologics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi
    Received grants for clinical research from: AbbVie Inc.; Dermira Inc.; Foamix; Galderma Laboratories, L.P.; LEO Pharma; Ortho Dermatologics; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; SolGel

  • Jacob P. Thyssen, MD, PhD

    Professor of Dermatology
    Herlev and Gentofte University Hospital
    University of Copenhagen, Denmark

    Disclosures

    Disclosure: Jacob P. Thyssen, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Eli Lilly & Company; LEO Pharma; Pfizer Inc.; Sanofi Genzyme Corporation
    Served as a speaker or a member of a speakers bureau for: LEO Pharma; Regeneron Pharmaceuticals, Inc.; Sanofi Genzyme Corporation
    Received grants for clinical research from: Regeneron Pharmaceuticals, Inc.
    Other: Spouse employed with Novo Nordisk

Editor

  • Lisette Arnaud-Hevi, PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Lisette Arnaud-Hevi, has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as advisor or consultant for: Viiv Healthcare
    Owns stocks, stock options, or bonds from: GSK

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Atopic Dermatitis Journal Club: What's New Now

Authors: Lawrence Eichenfield, MD; Emma Guttman-Yassky, MD, PhD; Linda Stein Gold, MD; Jacob P. Thyssen, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 11/23/2019

Valid for credit through: 11/23/2020

processing....

Contents of This CME Activity

 
 
 
 

Atopic Dermatitis Journal Club: What's New Now

Dr. Eichenfield introduces the Journal Club program
Lawrence Eichenfield, MD

Updates on FDA Approvals of AD Treatments

Dr Eichenfield discusses treatments for AD that were approved in 2019 by the FDA
Lawrence Eichenfield, MD

Updates on European Guidelines for the Treatment of AD and Disease Burden and QOL in Patients with AD

Dr. Thyssen discusses the status of the European Guidelines for AD management and the impact AD has on patient's quality of life
Jacob P. Thyssen, MD, PhD

Updates on Novel JAK inhibitors and Biologics Treatment for AD

Drs. Eichenfield and Guttman-Yassky discuss the data presented in 2019 on oral JAK inhibitors and Biologics treatments for AD
Lawrence Eichenfield, MD; Emma Guttman-Yassky, MD, PhD

2019 Highlights on Emerging Topical Treatments for AD

Drs. Eichenfield and Stein Gold discuss the data presented in 2019 on topical treatments in development for the management of AD
Lawrence Eichenfield, MD; Linda Stein Gold, MD

Updates on the Management of Pediatric Patients with AD

Dr. Eichenfield discusses the impact AD has on the pediatric patient population and their families
Lawrence Eichenfield, MD

Educational Impact Challenge

The goal of this activity is to review the latest data in atopic dermatitis (AD) published and presented at major dermatology and allergy meetings as well as discuss how the latest clinical data on therapies for AD can be integrated into clinical practice.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

  • Print